David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk.
David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech.
David Stermanon
Analyst Articles
Natural gas prices have been depressed for just a few years, but it feels like a lot longer. Numerous analysts (myself included) have tried to spot the bottom for this clean, abundant energy source, angling for the moment when supply comes down to… Read More
Even though we all track a select group of stocks on a regular basis, we still need to keep one eye on everything else happening in the investing sphere. Actions at another company may help to support — or erode — our confidence in a stock we’ve been tracking. For… Read More
Many investors say that you “shouldn’t try to catch a falling knife.” Well, I did, and it hurts. I made a big, bold $12,500 bet on Ford Motor (NYSE: F) when I launched my $100,000 Real-Money Portfolio late last year and am now paying the price… Read More
We’ve rarely seen such symmetry in stocks. In the first quarter of 2012, stocks zoomed ahead, almost to the very day that the quarter ended. Indeed, the S&P 500 hit its high mark for the year in the first trading session of the second quarter, and has been on the… Read More
Time to party like it’s…2007? No thanks. Just five years ago, the phrase “subprime” started to creep into the U.S. consumer lexicon. And not long after, the phrase “subprime mess” became a household name. #-ad_banner-#In case your memory needs refreshing, the subprime… Read More
After a steady six-month surge, the stock markets are reversing course. The S&P 500 is off roughly 5% since early April, and signs are emerging that there may be plenty more downside on the way. The problems for Greece — and Europe — keep mounting. The continent’s major economies have… Read More
Investors have been fretting about a weaker economy and the implications for economically-sensitive assets such as steel, copper, iron ore and other commodities. Indeed, the underlying spot prices for several key commodities are at multi-year lows and… Read More
Cooler heads have prevailed. A showdown between the executive branch of government and the judicial branch of government looked to usher in a new era of intra-governmental rancor that our Founding Fathers sought to avoid. But the Supreme Court’s decision to let much of the Obama Administration’s health care law… Read More
During the past two decades, management teams at virtually every major U.S. company have identified plans to move into foreign markets. Whereas in terms of population and purchasing power, the European market offers the same opportunity as the U.S. market,… Read More
Biotech investing is awfully tricky. For every stock pick that performs well, a number of others blow up. From increasingly tough hurdles with clinical trials to the mercurial rulings of the Food & Drug Administration (FDA), it’s a field littered with landmines. And it often requires deep medical knowledge to… Read More
